2026-2027呼吸道季节COVID-19疫苗有效性与安全性
该系统评价检索2025年8月至2026年6月四大数据库,纳入155篇文献(15项RCT、84项对照观察性研究、38项单组安全性研究、18项疾病负担描述性研究),评估美国许可COVID-19疫苗的有效性与安全性。结果显示更新版疫苗降低老年人(≥65岁,VE 53.0%)和成人(18-64岁,VE 54.0%)住院风险;孕妇接种降低自身急诊/紧急护理就诊风险(VE 58.0%)及婴儿出生后2个月内COVID-19相关住院接触(VE 50.0%-54.0%);9个月至4岁儿童急诊就诊风险降低(VE 76.0%);免疫抑制成人重症风险降低(VE 32.0%-53.0%);医护人员接种3-5剂较2剂降低实验室确诊COVID-19(VE 41.0%)和急性期后症状(VE 57.0%)。安全性方面,特别关注不良事件(卒中、血栓、心肌炎等)谱与既往综述一致,未报告新安全信号。
要点
- ≥65岁老年人接种更新版COVID-19疫苗,2025-2026季节住院风险降低53.0%(95%CI 37.0%-65.0%)。
- 18-64岁成人接种疫苗,2024-2025季节住院风险降低54.0%(95%CI 1.0%-78.0%)。
- 孕妇接种后自身COVID-19相关急诊/紧急护理就诊风险降低58.0%(95%CI 24.0%-77.0%),所生婴儿出生后2个月内COVID-19相关住院接触减少(VE 50.0%-54.0%),与接种孕周无关。
- 免疫抑制成人接种后重症COVID-19(ICU入住或死亡)风险降低32.0%-53.0%,取决于基础疾病等因素。
- 医护人员接种3-5剂较仅2剂,实验室确诊COVID-19风险降低41.0%(95%CI 34.0%-47.0%),急性期后COVID-19症状风险降低57.0%(95%CI 46.0%-66.0%)。
适用人群与场景
- 美国人群,包括≥65岁老年人、18-64岁成人、孕妇及其婴儿、9个月至4岁儿童、免疫抑制成人、医护人员。
- 纳入标准:报告美国许可COVID-19疫苗有效性、效力或安全性,或美国SARS-CoV-2流行病学的研究。
- 排除标准:原文未提及。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- ≥65岁老年人接种更新版疫苗,2025-2026季节住院VE 53.0%(95%CI 37.0%-65.0%);18-64岁成人2024-2025季节住院VE 54.0%(95%CI 1.0%-78.0%)。
- 孕妇接种后COVID-19相关急诊/紧急护理就诊VE 58.0%(95%CI 24.0%-77.0%);所生婴儿出生后2个月内COVID-19相关住院接触VE 50.0%-54.0%,与接种孕周无关。
- 9个月至4岁儿童接种后COVID-19相关急诊就诊VE 76.0%(95%CI 58.0%-87.0%)。
- 免疫抑制成人接种后重症COVID-19(ICU入住或死亡)VE 32.0%-53.0%,取决于基础疾病和其他因素。
- 医护人员接种3-5剂较2剂,实验室确诊COVID-19 VE 41.0%(95%CI 34.0%-47.0%),急性期后COVID-19症状VE 57.0%(95%CI 46.0%-66.0%)。
- 特别关注不良事件(如卒中、血栓、心肌炎)安全谱与既往综述一致;在延长基础免疫程序间隔的新指南下进行的研究未报告心肌炎或心包炎风险增加;未报告新安全信号。
证据类型、等级与局限
- 证据类型:系统评价,纳入15项随机临床试验、84项对照观察性研究、38项无对照单组产品安全性研究、18项描述性研究。
- 证据等级或推荐强度:原文未提及。
- 局限性:原文未明确说明;设计上包含大量观察性研究和无对照安全性研究。
对床旁实践的改变
- 对于≥65岁老年人、18-64岁成人、孕妇、9个月至4岁儿童、免疫抑制成人和医护人员,接种更新版COVID-19疫苗可降低住院、急诊就诊或重症风险,应据此支持接种决策。
- 医护人员接种3-5剂较2剂可进一步降低实验室确诊COVID-19和急性期后症状风险,支持完成多剂接种。
- 安全性方面未发现新信号,特别关注不良事件谱与既往一致,在延长基础免疫程序间隔的新指南下未报告心肌炎或心包炎风险增加。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: SARS-CoV-2 remains a substantial cause of respiratory illness, morbidity, and mortality. Evidence to date has demonstrated that COVID-19 vaccines reduce the risk of severe disease, including hospitalization and death.
OBJECTIVE: This systematic review identifies and summarizes newly published studies reporting on the effectiveness and safety of COVID-19 vaccines and COVID-19 epidemiology in the US.
EVIDENCE REVIEW: Cochrane Central Register of Controlled Trials, PubMed/MEDLINE, Embase, and Scopus were searched from August 1, 2025, through June 29, 2026. Studies were eligible if they reported on the effectiveness, efficacy, or safety of a US-licensed COVID-19 vaccine or SARS-CoV-2 epidemiology in the US.
FINDINGS: From 11 829 identified references, 155 publications were eligible (15 randomized clinical trials, 84 observational studies with a comparator group, 38 product safety studies without a comparator group [single group], and 18 descriptive studies of disease burden). Consistent with prior evidence, studies reported that updated COVID-19 vaccines were associated with a reduction in the risk of hospitalization among both older adults (≥65 years; vaccine effectiveness [VE], 53.0%; 95% CI, 37.0%-65.0%; 2025-2026 season) and adults (18-64 years; VE, 54.0%; 95% CI, 1.0%-78.0%; 2024-2025 season). Maternal vaccination was associated with reduced risk of COVID-19-associated emergency department/urgent care encounters among individuals vaccinated (VE, 58.0%; 95% CI, 24.0%-77.0%) and with fewer COVID-19-related hospital contacts in the first 2 months of life among infants born subsequently (VE range, 50.0%-54.0%), regardless of trimester of vaccination. Vaccination was also associated with a significant reduction in COVID-19-related pediatric emergency department visits (9 months to 4 years; VE, 76.0%; 95% CI, 58.0%-87.0%). Vaccination was associated with a reduced risk of critical COVID-19 illness (intensive care unit admission or death) in immunocompromised adults (VE range, 32.0%-53.0%, depending on condition and other factors). Health care personnel who received 3 to 5 vaccine doses were less likely to develop laboratory-confirmed COVID-19 illness (VE, 41.0%; 95% CI, 34.0%-47.0%) and postacute COVID-19 symptoms (VE, 57.0%; 95% CI, 46.0%-66.0%) compared with those who received only 2 doses. Across adverse events of special interest (eg, stroke, thrombosis, myocarditis), safety profiles were consistent with those of previous reviews. No identified studies conducted under the updated guidance on extended dosing intervals for the primary series reported an increased risk of myocarditis or pericarditis. No new safety signals were reported in the recently published studies eligible for this updated review of US-licensed COVID-19 vaccines.
CONCLUSIONS AND RELEVANCE: COVID-19 vaccines were consistently associated with a reduction in the risk of hospitalization and other outcomes, including among individuals at high risk of severe COVID-19, such as infants, and those who were pregnant. No new safety concerns were identified.
参考来源
- Lipson RA, Senerth E, Watson MA, et al. COVID-19 Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season. JAMA. 2026. PMID: 42684258. doi:10.1001/jama.2026.18191
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。